ARTICLE | Clinical News

Alkermes to start Phase III of Aripiprazole Lauroxil NanoCrystal Dispersion for schizophrenia

December 1, 2017 9:45 PM UTC

In October, Alkermes plc (NASDAQ:ALKS) said it will begin a double-blind, U.S. Phase IIIb trial of Aripiprazole Lauroxil NanoCrystal Dispersion (ALNCD) plus Aristada aripiprazole lauroxil vs. Invega Sustenna paliperidone palmitate from Johnson & Johnson (NYSE:JNJ) to treat acute exacerbation of schizophrenia.

ALNCD is designed to be given in conjunction with a single oral dose of aripiprazole to replace the need for 3 weeks of concomitant oral aripiprazole with the first dose of Aristada. Alkermes markets Aristada -- an injectable, extended-release formulation of aripiprazole using LinkeRx technology -- for schizophrenia...